Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (604)	12/18/2001 1:56:42 AM
From: Miljenko Zuanic	Respond to of 3559

jci.org J Clin Invest, December 2001, Volume 108, Number 12, 1735-1740 Copyright ©2001 by the American Society for Clinical Investigation -------------------------------------------------------------------------------- Perspective The central role of SOCS-3 in integrating the neuro-immunoendocrine interface Christoph J. Auernhammer1 and Shlomo Melmed2 1 Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany 2 Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, California, USA Address correspondence to: Shlomo Melmed, Academic Affairs, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA. Phone: (310) 423-4691; Fax: (310) 423-0119; E-mail: melmed@csmc.edu.